

FORM 7

MONTHLY PROGRESS REPORT

Name of CSE Issuer: Blueberries Medical Corp. (the "Company or "Issuer").

Trading Symbol: BBM

Number of Outstanding Listed Securities: 107,287,772

Date: **March 2019**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On February 5, the Issuer announced the completion of its business combination with Blueberries Cannabis Corp. (the "Private Company"), a leading Colombia-based licensed producer of medicinal cannabis and cannabis-derived products (the "Transaction"). Trading in the common shares of Blueberries (the "Blueberries Shares") commenced on the Canadian Securities Exchange (the "CSE") at market open on Wednesday, February 6, 2019 under the symbol "BBM", following the issuance by the CSE of its final bulletin in respect of the Transaction.

2. Provide a general overview and discussion of the activities of management.

On March 1, the Issuer filed its Financial Statements and Management's Discussion and Analysis for the third quarter ended December 31, 2018 on SEDAR (www.sedar.com).

On March 4, the Issuer announced that its common shares are now listed on the Frankfurt Stock Exchange (FSE) trading under the ticker symbol "10A".

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

N/A

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production

programs that have been amended or abandoned.

N/A

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

N/A

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

N/A

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

On March 26, the Issuer announced that it had entered into a binding agreement effective March 25, 2019 to acquire cannabis cultivation, processing, manufacturing, export and other rights in Argentina (the "Letter Agreement") from BBV Labs Inc. ("BBV Labs"). Pursuant to a definitive agreement with the Argentinian state-owned company Cannabis Avatara, S.E. ("Cannava"), BBV Labs has entered into a joint venture (the "Joint Venture") with Cannava to develop and cultivate cannabis on a 3.2 million square foot (74 acres or 30 hectares) prime agricultural property. Cannava will contribute the land to the Joint Venture as well as all required permits and authorizations necessary to import seeds, cultivate, grow and harvest cannabis, process cannabis and extract cannabis oil and other derivative products for scientific, medicinal and therapeutic purposes and to export cannabis and derivative products and import and export related equipment and products.

Highlights Include:

- **The rights to cannabis licenses in Argentina acquired by Blueberries are amongst very few such agreements currently in place to supply cannabis products to the Argentinian population exceeding 44 million people. The acquisition also expands the Company's production footprint internationally and may provide additional export opportunities to other countries with evolving cannabis regulations.**

- Blueberries to build a large-scale modern cultivation facility and processing centre of excellence in Argentina.
- Cannava will contribute all licenses/permits and authorizations necessary to import seeds, cultivate, grow and harvest cannabis, process cannabis, extract cannabis oil and other derivative products, export cannabis and derivative products, and import/export equipment and products.
- Cannava will grant access to utilize 3.2 million square foot (74 acres or 30 hectares) of prime agricultural land for the cultivation and growth of cannabis in Jujuy Province, Argentina, ideally situated in an area with robust modern infrastructure including fresh water, modern power supply and a nearby airport, with additional land available for potential future expansion.
- Cannava will contribute all cooperation agreements with the National Institute of Agricultural Technology (INTA), Ministry of Security, Ministry of Public Health, National Council of Scientific and Technological Investigations (CONICET) and other regulatory and technological Argentinian authorities as required.

8. Describe the acquisition of new customers or loss of customers.

N/A

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

N/A

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

N/A

11. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

N/A

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common Shares	665,000	Warrant Exercise	Working capital
Compensation shares	1,000,000	Share Grant	N/A
Options	3,600,000	Option Grant	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

N/A

16. Provide details of any changes in directors, officers or committee members.

On March 19, the Issuer announced the appointment of Fabio Valencia Cossio to its board of directors. Mr Valencia is a former Colombian Minister , Senator, and Ambassador to Italy with extensive strategic international business experience.

Since his tenure with the government, Mr. Valencia has been very active in the private sector where he currently provides legal and commercial consulting services to an extensive group of large multinational companies looking to grow their operations in South America. He is currently engaged with consumer product companies including Diageo plc, Pernod Ricard S.A. and Bacardi Limited. Mr. Valencia has also advised Ribera Salud Spain, a leading provider of health insurance services and Indra Sistemas S.A., Grupo Tradeco, Gilat Satellite Networks, Pacific Rubiales and Gran Colombia Gold.

On March 20, the Issuer announced the appointment of Dr. Patricio Stocker as Chief Executive Officer of the Company. Dr. Stocker is an accomplished executive with extensive international experience having led the successful development of numerous companies, including most recently PharmaCielo Ltd. (“PharmaCielo”), a leading Colombian producer of medicinal cannabis. Dr. Stocker joined PharmaCielo in 2015 and served as CEO through 2018. During his tenure of as CEO, Dr. Stocker was instrumental in the development of corporate strategies, formation of strategic relationships, the cannabis licensing process and capital raising initiatives. Dr. Stocker was also actively involved in the development of PharmaCielo’s Colombian operations to establish a scalable and competitive cultivation and oil production strategy.

The Issuer also announced that Mr. Christian Toro had been appointed Executive Chairman of the Board.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

N/A


Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 3, 2019

Camilo Villalba
Name of Director or Senior Officer



Signature

Chief Operating Officer
Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer		End	YY/MM/DD
Blueberries Medical Corp.		March 2019	2019/04/03
Issuer Address			
885 West Georgia Street, Suite 2200, HSBC Building			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6C 3E8			
Contact Name		Contact Position	Contact Telephone No.
Camilo Villalba		COO	+57 3134830131
Contact Email Address		Web Site Address	
cvillalba@blueberriesmed.com		www.blueberriesmed.com	